Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Shareholders' (Deficit) Equity

v3.26.1
Condensed Consolidated Statements of Shareholders' (Deficit) Equity - USD ($)
$ in Thousands
Total
Series B Conversion
Preferred Class B
Common Stock
Common Stock
Series B Conversion
Preferred Stock
Preferred Class B
Preferred Stock
Preferred Class B
Series B Conversion
Additional Paid-in Capital
Additional Paid-in Capital
Series B Conversion
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Non-controlling Interest
Non-controlling Interest
Series B Conversion
Common stock, beginning balance (in shares) at Dec. 31, 2024       29,761,000                  
Beginning balance at Dec. 31, 2024 $ 285,868     $ 298   $ 0   $ 542,392   $ (2,732) $ (338,230) $ 84,140  
Preferred stock, beginning balance (in shares) at Dec. 31, 2024           10,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss (61,191)                   (50,637) (10,554)  
Foreign currency translation adjustments 265                 265      
Issuance of share-based awards (in shares)       97,000                  
Payment of minimum tax withholdings on share-based awards and other (in shares)       (30,000)                  
Payment of minimum tax withholdings on share-based awards and other (894)                   (894)    
Series B conversions (in shares)         585,000   (1,000)            
Series B conversions   $ 0     $ 6       $ 1,208       $ (1,214)
Share-based compensation expense 2,958             2,958          
Common stock, ending balance (in shares) at Mar. 31, 2025       30,413,000                  
Preferred stock, ending balance (in shares) at Mar. 31, 2025           9,000              
Ending balance at Mar. 31, 2025 227,006     $ 304   $ 0   546,558   (2,467) (389,761) 72,372  
Common stock, beginning balance (in shares) at Dec. 31, 2024       29,761,000                  
Beginning balance at Dec. 31, 2024 285,868     $ 298   $ 0   542,392   (2,732) (338,230) 84,140  
Preferred stock, beginning balance (in shares) at Dec. 31, 2024           10,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss (81,555)                        
Foreign currency translation adjustments 4,826                        
Common stock, ending balance (in shares) at Jun. 30, 2025       30,607,000                  
Preferred stock, ending balance (in shares) at Jun. 30, 2025           9,000              
Ending balance at Jun. 30, 2025 216,241     $ 306   $ 0   551,845   2,094 (402,451) 64,447  
Common stock, beginning balance (in shares) at Mar. 31, 2025       30,413,000                  
Beginning balance at Mar. 31, 2025 227,006     $ 304   $ 0   546,558   (2,467) (389,761) 72,372  
Preferred stock, beginning balance (in shares) at Mar. 31, 2025           9,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss (20,364)                   (12,583) (7,781)  
Foreign currency translation adjustments 4,561                 4,561      
Issuance of share-based awards (in shares)       99,000                  
Payment of minimum tax withholdings on share-based awards and other (in shares)       (2,000)                  
Payment of minimum tax withholdings on share-based awards and other (107)                   (107)    
Series B conversions (in shares)         80,000                
Series B conversions   0     $ 1       143       (144)
Share-based compensation expense 4,711             4,711          
Common stock issued under employee stock purchase plan (in shares)       17,000                  
Common stock issued under employee stock purchase plan 434     $ 1       433          
Common stock, ending balance (in shares) at Jun. 30, 2025       30,607,000                  
Preferred stock, ending balance (in shares) at Jun. 30, 2025           9,000              
Ending balance at Jun. 30, 2025 $ 216,241     $ 306   $ 0   551,845   2,094 (402,451) 64,447  
Common stock, beginning balance (in shares) at Dec. 31, 2025 31,327,000     31,327,000                  
Beginning balance at Dec. 31, 2025 $ 161,664     $ 313   $ 0   559,551   580 (447,100) 48,320  
Preferred stock, beginning balance (in shares) at Dec. 31, 2025 0   9,000     9,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss $ (40,198)                   (34,319) (5,879)  
Foreign currency translation adjustments (2,046)                 (1,610)   (436)  
Issuance of share-based awards (in shares)       191,000                  
Issuance of share-based awards 0     $ 2       (2)          
Payment of minimum tax withholdings on share-based awards and other (in shares)       (53,000)                  
Payment of minimum tax withholdings on share-based awards and other (685)             807     (1,492)    
Series B conversions (in shares)         133,000                
Series B conversions   0     $ 1       729       (730)
Share-based compensation expense 3,541             3,541          
Common stock, ending balance (in shares) at Mar. 31, 2026       31,598,000                  
Preferred stock, ending balance (in shares) at Mar. 31, 2026           9,000              
Ending balance at Mar. 31, 2026 $ 122,276     $ 316   $ 0   564,626   (1,030) (482,911) 41,275  
Common stock, beginning balance (in shares) at Dec. 31, 2025 31,327,000     31,327,000                  
Beginning balance at Dec. 31, 2025 $ 161,664     $ 313   $ 0   559,551   580 (447,100) 48,320  
Preferred stock, beginning balance (in shares) at Dec. 31, 2025 0   9,000     9,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss $ (286,129)                        
Foreign currency translation adjustments $ (2,181)                        
Common stock, ending balance (in shares) at Jun. 30, 2026 33,736,000     33,736,000                  
Preferred stock, ending balance (in shares) at Jun. 30, 2026 0   7,000     7,000              
Ending balance at Jun. 30, 2026 $ (122,666)     $ 337   $ 0   575,818   (1,261) (690,324) (7,236)  
Common stock, beginning balance (in shares) at Mar. 31, 2026       31,598,000                  
Beginning balance at Mar. 31, 2026 122,276     $ 316   $ 0   564,626   (1,030) (482,911) 41,275  
Preferred stock, beginning balance (in shares) at Mar. 31, 2026           9,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Net loss (245,931)                   (207,300) (38,631)  
Foreign currency translation adjustments (135)                 (231)   96  
Issuance of share-based awards (in shares)       55,000                  
Payment of minimum tax withholdings on share-based awards and other (in shares)       (5,000)                  
Payment of minimum tax withholdings on share-based awards and other (101)             12     (113)    
Series B conversions (in shares)         2,059,000   (2,000)            
Series B conversions   $ 0     $ 21       $ 9,955       $ (9,976)
Share-based compensation expense 491             491          
Common stock issued under employee stock purchase plan (in shares)       29,000                  
Common stock issued under employee stock purchase plan $ 734             734          
Common stock, ending balance (in shares) at Jun. 30, 2026 33,736,000     33,736,000                  
Preferred stock, ending balance (in shares) at Jun. 30, 2026 0   7,000     7,000              
Ending balance at Jun. 30, 2026 $ (122,666)     $ 337   $ 0   $ 575,818   $ (1,261) $ (690,324) $ (7,236)